Rita Vandivort-Warren
Substance Abuse and Mental Health Services Administration
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Rita Vandivort-Warren.
Drug and Alcohol Dependence | 2009
Tami L. Mark; Cheryl A. Kassed; Rita Vandivort-Warren; Katharine R. Levit; Henry R. Kranzler
Over the past decade, advances in addiction neurobiology have led to the approval of new medications to treat alcohol and opioid dependence. This study examined data from the IMS National Prescription Audit (NPA) Plus database of retail pharmacy transactions to evaluate trends in U.S. retail sales and prescriptions of FDA-approved medications to treat substance use disorders. Data reveal that prescriptions for alcoholism medications grew from 393,000 in 2003 (
Health Affairs | 2011
Tami L. Mark; Katharine R. Levit; Rita Vandivort-Warren; Jeffrey A. Buck; Rosanna M. Coffey
30 million in sales) to an estimated 720,000 (
Journal of Substance Abuse Treatment | 2012
Ellen Bouchery; Henrick J. Harwood; Joan Dilonardo; Rita Vandivort-Warren
78 million in sales) in 2007. The growth was largely driven by the introduction of acamprosate in 2005, which soon became the market leader (
Psychiatric Services | 2012
Tami L. Mark; Cheryl A. Kassed; Katharine R. Levit; Rita Vandivort-Warren
35 million in sales). Prescriptions for the two buprenorphine formulations increased from 48,000 prescriptions (
Journal of Behavioral Health Services & Research | 2008
Tami L. Mark; Henrick J. Harwood; David C. McKusick; Edward C. King; Rita Vandivort-Warren; Jeffrey A. Buck
5 million in sales) in the year of their introduction (2003) to 1.9 million prescriptions (
Drug and Alcohol Dependence | 2012
Tami L. Mark; Rita Vandivort-Warren
327 million in sales) in 2007. While acamprosate and buprenorphine grew rapidly after market entry, overall substance abuse retail medication sales remain small relative to the size of the population that could benefit from treatment and relative to sales for other medications, such as antidepressants. The extent to which substance dependence medications will be adopted by physicians and patients, and marketed by industry, remains uncertain.
Evaluation Review | 2009
Rosanna M. Coffey; Katharine R. Levit; Cheryl A. Kassed; A. Thomas McLellan; Mady Chalk; Thomas M. Brady; Rita Vandivort-Warren
The United States invests a sizable amount of money on treatments for mental health and substance abuse:
Journal of Substance Abuse Treatment | 2006
Tami L. Mark; Rita Vandivort-Warren; Leslie B. Montejano
135 billion in 2005, or 1.07 percent of the gross domestic product. We provide treatment spending estimates from the period 1986-2005 to build understanding of past trends and consider future possibilities. We find that the growth rate in spending on mental health medications-a major driver of mental health expenditures in prior years-declined dramatically. As a result, mental health and substance abuse spending grew at a slightly slower rate than gross domestic product in 2004 and 2005, and it continued to shrink as a share of all health spending. Of note, we also find that Medicaids share of total spending on mental health grew from 17 percent in 1986 to 27 percent in 2002 to 28 percent in 2005. The recent recession, the full implementation of federal parity law, and such health reform-related actions as the planned expansion of Medicaid all have the potential to improve access to mental health and substance abuse treatment and to alter spending patterns further. Our spending estimates provide an important context for evaluating the effect of those policies.
Health Affairs | 2005
Tami L. Mark; Rosanna M. Coffey; Rita Vandivort-Warren; Hendrick J. Harwood; Edward C. King
OBJECTIVE Most individuals reporting symptoms consistent with substance use disorders do not receive care. This study examines the correlation between type of insurance coverage and receipt of substance abuse treatment, controlling for other observable factors that may influence treatment receipt. METHOD Descriptive and multivariate analyses are conducted using pooled observations from the 2002-2007 editions of the National Survey on Drug Use and Health. The likelihood of treatment entry is estimated by type of insurance coverage controlling for personal characteristics and characteristics of the individuals substance use disorder. RESULTS Multivariate analyses that control for type of substance and severity of disorder (dependence vs. abuse) find that those with Civilian Health and Medical Program of the Uniformed Services/Veterans Affairs, Medicaid only, Medicare only, and Medicare and Medicaid (dual eligibles) have 50% to almost 90% greater odds of receiving treatment relative to those with private insurance. CONCLUSIONS The privately insured population has substantially lower treatment entry rates than those with publicly provided insurance. Additional research is warranted to understand the source of the differences across insurance types so that improvements can be achieved.
Health Affairs | 2007
Tami L. Mark; Katharine R. Levit; Rita Vandivort-Warren; Rosanna M. Coffey; Jeffrey A. Buck
OBJECTIVE This study analyzed recent trends in spending on psychiatric prescription drugs and underlying factors that served as drivers of these changes. METHODS Data were collected from the MarketScan Commercial Claims and Encounters Database (1997-2008), Substance Abuse and Mental Health Services Administration spending estimates (1986-2005), and the Medical Expenditure Panel Survey (1997-2007). The trends in medication spending derived from the data were decomposed into three categories: percentage of enrollees who used psychiatric medications, days supplied per user, and cost per day supplied. RESULTS The average annual rate of growth in expenditures per enrollee slowed from 18.5% in 1997-2001 to 6.3% in 2001-2008. A decline in the growth rate of cost per day supplied, from 8% to 2%, accounted for 49% of the overall decline in spending growth, and a decline in the growth of the percentage of enrollees who used medication, from 7% to 2%, contributed 41% to the overall decline. There was a smaller change in days supplied per user, from 3% to 2%, that contributed 10% to the overall decline. The increased entry of generic medications, which constituted 70% of all psychiatric prescriptions by 2008, particularly generic antidepressants, was a key contributor to the slower growth in costs. CONCLUSIONS Past high growth in psychiatric drug spending arising from growth in utilization of branded medications has declined significantly, which may have implications for access and new product investment.
Collaboration
Dive into the Rita Vandivort-Warren's collaboration.
Substance Abuse and Mental Health Services Administration
View shared research outputsSubstance Abuse and Mental Health Services Administration
View shared research outputsSubstance Abuse and Mental Health Services Administration
View shared research outputsSubstance Abuse and Mental Health Services Administration
View shared research outputsSubstance Abuse and Mental Health Services Administration
View shared research outputs